000 04342naa a22006497i 4500
001 UMUN-OA-20261005-MLS-032
003 local
005 20261005174904.0
006 m o d
007 cr||||||||||||
008 261005s2023 xx o u000 0 eng d
024 7 _a10.1186/s12967-023-04292-3
_2doi
035 _a(local)EuropePMC:PMC10327392
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aGunjan Dagar
_eauthor.
245 1 0 _aHarnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. /
_cGunjan Dagar; Ashna Gupta; Tariq Masoodi [and others].
264 1 _a[Place of publication not identified] :
_bBMC,
_c2023.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aThe source lists 17 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest.
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aTraditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells.
540 _aCreative Commons Attribution. See the linked licence for the applicable terms.
_uhttps://creativecommons.org/licenses/by/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
650 4 _aTumor antigens
650 4 _aImmunotherapy
650 4 _aHematological malignancy
650 4 _aSolid tumor
650 4 _aCytokine Release Syndrome
650 4 _aAntigen Escape
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _ahematology
655 4 _aReview articles.
700 0 _aAshna Gupta
_eauthor.
700 0 _aTariq Masoodi
_eauthor.
700 0 _aSabah Nisar
_eauthor.
700 0 _aMaysaloun Merhi
_eauthor.
700 0 _aSheema Hashem
_eauthor.
700 0 _aRavi Chauhan
_eauthor.
700 0 _aManisha Dagar
_eauthor.
700 0 _aSameer Mirza
_eauthor.
700 0 _aPuneet Bagga
_eauthor.
700 0 _aRakesh Kumar
_eauthor.
700 0 _aAmmira S Al-Shabeeb Akil
_eauthor.
773 0 _tJournal of translational medicine
_gVol. 21, no. 1, (2023), pages/article 449
_x1479-5876
856 4 0 _uhttps://europepmc.org/articles/PMC10327392
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC10327392
_qlocal
942 _n0
999 _c1174
_d1174